HC Wainwright Lowers Spero Therapeutics (NASDAQ:SPRO) Price Target to $5.00

Spero Therapeutics (NASDAQ:SPRO) had its price objective reduced by equities research analysts at HC Wainwright from $7.00 to $5.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 281.68% from the company’s current price.

Several other equities analysts also recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Tuesday, August 6th. TD Cowen upgraded Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th.

Spero Therapeutics Stock Performance

NASDAQ:SPRO opened at $1.31 on Monday. Spero Therapeutics has a 52 week low of $1.01 and a 52 week high of $1.89. The firm’s fifty day moving average is $1.30 and its 200-day moving average is $1.37. The firm has a market cap of $70.72 million, a P/E ratio of 3.97 and a beta of 0.63.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Monday, August 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. Spero Therapeutics had a net margin of 14.74% and a return on equity of 25.67%. The company had revenue of $10.20 million for the quarter, compared to the consensus estimate of $9.80 million. During the same quarter in the previous year, the company earned ($0.23) EPS. As a group, sell-side analysts anticipate that Spero Therapeutics will post -1.59 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SPRO. Vanguard Group Inc. lifted its position in shares of Spero Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after acquiring an additional 9,675 shares in the last quarter. Murchinson Ltd. lifted its holdings in Spero Therapeutics by 1.3% during the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after purchasing an additional 11,210 shares in the last quarter. Virtu Financial LLC purchased a new stake in Spero Therapeutics during the 1st quarter worth about $31,000. Renaissance Technologies LLC boosted its stake in Spero Therapeutics by 14.2% in the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after purchasing an additional 121,492 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in Spero Therapeutics by 40.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock valued at $1,392,000 after buying an additional 309,262 shares in the last quarter. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.